Sequence variation in PPARG may underlie differential response to troglitazone

Diabetes

Volumn 54, Issue 11, 2005, Pages 3319-3325

  Wolford, Johanna K ^a   Yeatts, Kimberly A ^a   Dhanjal, Sharanjeet K ^b   Black, Mary Helen ^b   Xiang, Anny H ^b   Buchanan, Thomas A ^b   Watanabe, Richard M ^b  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TROGLITAZONE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DRUG RESPONSE; FEMALE; GENE DELETION; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; CHROMANS; DIABETES MELLITUS, TYPE 2; FEMALE; HAPLOTYPES; HUMANS; HYPOGLYCEMIC AGENTS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 33644669582     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.54.11.3319     Document Type: Article

References (28)

1. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, the Pioglitazone 001 Study Group: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 23:1605-1611, 2000
2. Lawrence JM, Reckless JPD: Pioglitazone. Int J Clin Pract 54:614-618, 2000
3. Baba S: Pioglitazone: a review of Japanese clinical studies. Curr Med Res Opion 17:166-189, 2001
4. Goldstein BJ: Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metab Res Rev 18:S16-S22, 2002
5. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
6. Antonucci T, Whitcomb R, McLain R, Lockwood D: Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 20:188-193, 1997
7. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299-3306, 1996
8. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796-2803, 2002
9. Azen SP, Peters RK, Berkowitz K, Kjos SL, Xiang A, Buchanan TA, the TRIPOD Study Group: TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19:217-231, 1998
10. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, Goico J, Ochoa C, Azen SP: Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 49:782-788, 2000
11. Scherbaum WA, Göke B, the German Pioglitazone Study Group: Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 34:589-595, 2002
12. Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jimenez F, Hardin PA, Konkoy CS, Tan MH, the GLAB Study Group: A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 25:1074-1095, 2003
13. Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA: Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala PPAR-γ-2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 27:1365-1368, 2004
14. Blüher M, Lübben G, Paschke R: Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 26:825-831, 2003
15. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl M-C, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80, 2000
16. Barroso I, Luan J, Middelberg RPS, Harding AH, Franks PW, Jakes RW, Clayton D, Schafer AJ, O'Rahilly S, Wareham NJ: Candidate gene association study in type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action. PLOS Biol 1:41-55, 2003
17. O'Rahilly S, Barroso I, Wareham NJ: Genetic factors in type 2 diabetes: the end of the beginning? Science 307:370-373, 2005
18. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265, 2005
19. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science 296:2225-2229, 2002
20. Clark AG: Inference of haplotypes from PCR-amplified samples of diploid populations. Mol Biol Evol 7:111-122, 1990
21. Kang ES, Park SY, Kim HJ, Ahn CW, Nam M, Cha BS, Lim SK, Kim KR, Lee HC: The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 28:1139-1144, 2005
22. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
23. Otto C, Lehrke M, Göke B: Novel insulin sensitizers: pharmacogenomic aspects. Pharmacogenomics J 3:99-116, 2003
24. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y: Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912, 1999
25. Kelly IE, Han TS, Walsh K, Lean MEJ: Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293, 1999
26. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K: Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23:1067-1071, 2000
27. de Dios ST, Hannan KM, Dilley RJ, Hill MA, Little PJ: Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J Diabetes Complications 15:120-127, 2001
28. Chen L, Yang B, McNulty JA, Clifton LG, Binz JG, Grimes AM, Strum JC, Wallace Harrington W, Chen Z, Balon TW, Stimpson SA, Brown KK: GI262570, a peroxisome proliferator-activated receptor γ agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Therap 312:718-725, 2005